Clinical and Methodologic Considerations With Regard to a Trial of Nintedanib in Patients With Systemic Sclerosis‐Associated Interstitial Lung Disease: Comment on the Reanalysis by Maher et al. Issue 12 (20th October 2021) - Bredemeier, Markus